Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Vasilios G. Athyros, Konstantinos Tziomalos, Georgios N. Daskalopoulos, Asterios Karagiannis & Dimitri P. Mikhailidis. (2011) Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?. Annals of Medicine 43:3, pages 167-171.
Read now
Read now
David C. Klonoff, John B. Buse, Loretta L. Nielsen, Xuesong Guan, Christopher L. Bowlus, John H. Holcombe, Matthew E. Wintle & David G. Maggs. (2008) Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Current Medical Research and Opinion 24:1, pages 275-286.
Read now
Read now
Flavia D Mendes & Keith D Lindor. (2005) Recent advances in the treatment of non-alcoholic fatty liver disease. Expert Opinion on Investigational Drugs 14:1, pages 29-35.
Read now
Read now
Articles from other publishers (19)
Trinita K. Barboza, Leonardo Susta, Alex zur Linden, Sara Gardhouse & Hugues Beaufrère. (2023) Association of plasma metabolites and diagnostic imaging findings with hepatic lipidosis in bearded dragons (Pogona vitticeps) and effects of gemfibrozil therapy. PLOS ONE 18:2, pages e0274060.
Crossref
Crossref
Hyunji Lee, Gyeyeong Kong, Quangdon Tran, Chaeyeong Kim, Jisoo Park & Jongsun Park. (2020) Relationship Between Ginsenoside Rg3 and Metabolic Syndrome. Frontiers in Pharmacology 11.
Crossref
Crossref
Mohammad Bagherniya, Valerio Nobili, Christopher N. Blesso & Amirhossein Sahebkar. (2018) Medicinal plants and bioactive natural compounds in the treatment of non-alcoholic fatty liver disease: A clinical review. Pharmacological Research 130, pages 213-240.
Crossref
Crossref
Qian Zhang. (2015)
3.0T
1
H magnetic resonance spectroscopy for assessment of steatosis in patients with chronic hepatitis C
. World Journal of Gastroenterology 21:21, pages 6736.
Crossref
Crossref
B Jorgačević, D Mladenović, M Ninković, V Prokić, MN Stanković, V Aleksić, I Cerović, R Ješić Vukićević, D Vučević, M Stanković & T Radosavljević. (2013) Dynamics of oxidative/nitrosative stress in mice with methionine–choline-deficient diet-induced nonalcoholic fatty liver disease. Human & Experimental Toxicology 33:7, pages 701-709.
Crossref
Crossref
Angelo H. Paredes, Dawn M. Torres & Stephen A. Harrison. (2012) Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 16:2, pages 397-419.
Crossref
Crossref
Eun-Jung Rhee, Won-Young Lee, Yong-Kyun Cho, Byung-Ik Kim & Ki-Chul Sung. (2011) Hyperinsulinemia and the Development of Nonalcoholic Fatty Liver Disease in Nondiabetic Adults. The American Journal of Medicine 124:1, pages 69-76.
Crossref
Crossref
Yu YamazakiIsao UsuiYukiko KanataniYuji MatsuyaKoichi TsuneyamaShiho FujisakaAgussalim BukhariHikari SuzukiSatoko SendaShingo ImanishiKazuya HirataManabu IshikiRyuji HayashiMasaharu UrakazeHideo NemotoMasashi Kobayashi & Kazuyuki Tobe. (2009) Treatment with SRT1720, a SIRT1 activator, ameliorates fatty liver with reduced expression of lipogenic enzymes in MSG mice. American Journal of Physiology-Endocrinology and Metabolism 297:5, pages E1179-E1186.
Crossref
Crossref
Yu Wang, Mingyan Zhou, Karen S. L. Lam & Aimin Xu. (2009) Protective roles of adiponectin in obesity-related fatty liver diseases: mechanisms and therapeutic implications. Arquivos Brasileiros de Endocrinologia & Metabologia 53:2, pages 201-212.
Crossref
Crossref
Guang Ji. (2008) Effectiveness of Danning Tablet in patients with non-alcoholic fatty liver of damp-heat syndrome type: A multicenter randomized controlled trial. Journal of Chinese Integrative Medicine 6:2, pages 128-133.
Crossref
Crossref
Scott D. Mendelson. 2008. Metabolic Syndrome and Psychiatric Illness. Metabolic Syndrome and Psychiatric Illness
141
186
.
Anna Mae Diehl & Steve S. Choi. 2008. Type 2 Diabetes Mellitus. Type 2 Diabetes Mellitus
351
364
.
Leon A. Adams & Keith D. Lindor. (2007) Nonalcoholic Fatty Liver Disease. Annals of Epidemiology 17:11, pages 863-869.
Crossref
Crossref
John B. Buse, David C. Klonoff, Loretta L. Nielsen, Xuesong Guan, Christopher L. Bowlus, John H. Holcombe, David G. Maggs & Matthew E. Wintle. (2007) Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clinical Therapeutics 29:1, pages 139-153.
Crossref
Crossref
Paul Angulo. (2006) Nonalcoholic fatty liver disease and liver transplantation. Liver Transplantation 12:4, pages 523-534.
Crossref
Crossref
Anna Wieckowska & Ariel E Feldstein. (2005) Nonalcoholic fatty liver disease in the pediatric population: a review. Current Opinion in Pediatrics 17:5, pages 636-641.
Crossref
Crossref
Jian-Gao Fan. (2005) Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia. World Journal of Gastroenterology 11:15, pages 2346.
Crossref
Crossref
Stuart AS Craig. (2004) Betaine in human nutrition. The American Journal of Clinical Nutrition 80:3, pages 539-549.
Crossref
Crossref
Isabelle A. Leclercq & Yves Horsmans. 2004. Fatty Liver Disease. Fatty Liver Disease
143
158
.